HC Wainwright Has Negative View of Verona Pharma Q4 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Research analysts at HC Wainwright lowered their Q4 2025 earnings per share estimates for shares of Verona Pharma in a note issued to investors on Wednesday, April 30th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.02 per share for the quarter, down from their previous estimate of $0.08. HC Wainwright currently has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million.

Several other analysts have also recently issued reports on VRNA. Roth Capital set a $83.00 target price on Verona Pharma in a research report on Friday, February 28th. Truist Financial reaffirmed a "buy" rating and set a $57.00 price objective (up previously from $44.00) on shares of Verona Pharma in a research report on Wednesday, January 8th. Roth Mkm started coverage on shares of Verona Pharma in a report on Friday, January 10th. They issued a "buy" rating and a $68.00 target price for the company. TD Cowen assumed coverage on shares of Verona Pharma in a report on Monday, April 28th. They issued a "buy" rating and a $100.00 price target on the stock. Finally, Wells Fargo & Company boosted their price objective on shares of Verona Pharma from $93.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $81.50.

Verona Pharma Stock Up 0.7 %

Shares of NASDAQ VRNA traded up $0.47 during midday trading on Thursday, reaching $72.73. 1,449,011 shares of the company's stock traded hands, compared to its average volume of 1,270,611. The company has a market cap of $5.88 billion, a price-to-earnings ratio of -37.88 and a beta of 0.20. The stock's 50 day simple moving average is $63.10 and its 200-day simple moving average is $52.02. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. Verona Pharma has a one year low of $11.39 and a one year high of $74.18.

Institutional Trading of Verona Pharma

Several large investors have recently added to or reduced their stakes in the company. NBC Securities Inc. acquired a new stake in shares of Verona Pharma during the first quarter worth about $34,000. Vermillion Wealth Management Inc. acquired a new stake in Verona Pharma during the 4th quarter valued at approximately $46,000. GF Fund Management CO. LTD. acquired a new stake in Verona Pharma during the 4th quarter valued at approximately $72,000. GAMMA Investing LLC increased its stake in shares of Verona Pharma by 20.7% in the fourth quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock worth $75,000 after acquiring an additional 276 shares during the period. Finally, Avanza Fonder AB acquired a new stake in shares of Verona Pharma in the first quarter worth $100,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Insider Activity

In other Verona Pharma news, insider Kathleen A. Rickard sold 79,264 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $8.35, for a total transaction of $661,854.40. Following the sale, the insider now owns 2,608,976 shares of the company's stock, valued at approximately $21,784,949.60. The trade was a 2.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Andrew Fisher sold 26,072 shares of the company's stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $8.98, for a total transaction of $234,126.56. Following the transaction, the general counsel now owns 359,993 shares in the company, valued at $3,232,737.14. The trade was a 6.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 250,080 shares of company stock worth $2,194,582 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.